JP2013518864A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518864A5 JP2013518864A5 JP2012551647A JP2012551647A JP2013518864A5 JP 2013518864 A5 JP2013518864 A5 JP 2013518864A5 JP 2012551647 A JP2012551647 A JP 2012551647A JP 2012551647 A JP2012551647 A JP 2012551647A JP 2013518864 A5 JP2013518864 A5 JP 2013518864A5
- Authority
- JP
- Japan
- Prior art keywords
- amine
- triazin
- compound
- formula
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30206010P | 2010-02-05 | 2010-02-05 | |
| US61/302,060 | 2010-02-05 | ||
| US38176410P | 2010-09-10 | 2010-09-10 | |
| US61/381,764 | 2010-09-10 | ||
| PCT/EP2011/051755 WO2011095625A1 (en) | 2010-02-05 | 2011-02-07 | 1,2,4-triazine-4-amine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013518864A JP2013518864A (ja) | 2013-05-23 |
| JP2013518864A5 true JP2013518864A5 (enExample) | 2016-04-07 |
| JP5914361B2 JP5914361B2 (ja) | 2016-05-11 |
Family
ID=43837724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012551647A Active JP5914361B2 (ja) | 2010-02-05 | 2011-02-07 | １，２，４−トリアジン−４−アミン含有誘導体 |
Country Status (24)
| Country | Link |
|---|---|
| US (6) | US8809525B2 (enExample) |
| EP (1) | EP2531492B1 (enExample) |
| JP (1) | JP5914361B2 (enExample) |
| KR (2) | KR101993867B1 (enExample) |
| CN (1) | CN102822150B (enExample) |
| AU (1) | AU2011212430B2 (enExample) |
| BR (1) | BR112012019540B1 (enExample) |
| CA (1) | CA2789279C (enExample) |
| CY (1) | CY1117780T1 (enExample) |
| DK (1) | DK2531492T3 (enExample) |
| ES (1) | ES2579949T3 (enExample) |
| HR (1) | HRP20160636T1 (enExample) |
| HU (1) | HUE028640T2 (enExample) |
| IL (1) | IL221160A (enExample) |
| MX (1) | MX352415B (enExample) |
| MY (1) | MY180024A (enExample) |
| PL (1) | PL2531492T3 (enExample) |
| PT (1) | PT2531492T (enExample) |
| RU (1) | RU2625791C2 (enExample) |
| SG (1) | SG183146A1 (enExample) |
| SI (1) | SI2531492T1 (enExample) |
| SM (1) | SMT201600198B (enExample) |
| WO (1) | WO2011095625A1 (enExample) |
| ZA (1) | ZA201205788B (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2531492T3 (en) | 2010-02-05 | 2016-07-04 | Heptares Therapeutics Ltd | 1,2,4-triazin-4-amine derivatives |
| AU2012220558A1 (en) | 2011-02-23 | 2013-08-22 | Massachusetts Institute Of Technology | Water soluble membrane proteins and methods for the preparation and use thereof |
| CN104341386A (zh) * | 2013-07-23 | 2015-02-11 | 中国科学院上海药物研究所 | 一类芳基杂环小分子化合物、其衍生物及其制备方法和用途 |
| US10373702B2 (en) | 2014-03-27 | 2019-08-06 | Massachusetts Institute Of Technology | Water-soluble trans-membrane proteins and methods for the preparation and use thereof |
| US10184794B2 (en) * | 2015-07-01 | 2019-01-22 | Makita Corporation | Laser marker |
| TW201827422A (zh) | 2017-01-13 | 2018-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | １，２，４－三嗪－３－胺類衍生物、其製備方法及其在醫藥上的應用 |
| CN108467386B (zh) * | 2017-02-23 | 2020-11-17 | 江苏恒瑞医药股份有限公司 | 稠杂芳基取代的1,2,4-三嗪-3-胺类衍生物、其制备方法及其在医药上的应用 |
| WO2018166493A1 (zh) | 2017-03-16 | 2018-09-20 | 江苏恒瑞医药股份有限公司 | 杂芳基并[4，3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用 |
| US11312783B2 (en) | 2017-06-22 | 2022-04-26 | Novartis Ag | Antibody molecules to CD73 and uses thereof |
| WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES |
| BR112020000962A2 (pt) | 2017-07-18 | 2020-07-14 | Nuvation Bio Inc. | compostos de 1,8-naftiridinona e usos dos mesmos |
| JP2020527588A (ja) * | 2017-07-18 | 2020-09-10 | ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． | アデノシンアンタゴニストとしてのヘテロ環式化合物 |
| KR102636383B1 (ko) | 2017-08-04 | 2024-02-14 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| WO2019072143A1 (zh) * | 2017-10-11 | 2019-04-18 | 上海迪诺医药科技有限公司 | 4-氨基吡啶衍生物、其药物组合物、制备方法及应用 |
| CN111655288A (zh) | 2017-11-16 | 2020-09-11 | 诺华股份有限公司 | 组合疗法 |
| WO2019108900A1 (en) | 2017-11-30 | 2019-06-06 | Novartis Ag | Bcma-targeting chimeric antigen receptor, and uses thereof |
| JP2021512959A (ja) | 2018-02-06 | 2021-05-20 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． | ピラゾロ［１，５−ａ］［１，３，５］トリアジン−２−アミン誘導体、その製造法、およびその医薬用途 |
| WO2019158070A1 (zh) * | 2018-02-15 | 2019-08-22 | 杭州阿诺生物医药科技有限公司 | A2a和/或a2b受体拮抗剂 |
| CN111440148B (zh) * | 2018-02-15 | 2021-07-30 | 杭州阿诺生物医药科技有限公司 | 一种腺苷受体拮抗剂的制备方法 |
| US10738128B2 (en) | 2018-03-14 | 2020-08-11 | Surface Oncology, Inc. | Antibodies that bind CD39 and uses thereof |
| UY38247A (es) | 2018-05-30 | 2019-12-31 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| AU2019277029C1 (en) | 2018-06-01 | 2024-01-04 | Novartis Ag | Binding molecules against BCMA and uses thereof |
| CN110655509B (zh) * | 2018-06-29 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | 2-胺基嘧啶类衍生物、其制备方法及其在医药上的应用 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| WO2020011220A1 (zh) * | 2018-07-12 | 2020-01-16 | 江苏恒瑞医药股份有限公司 | 杂芳基类衍生物、其制备方法及其在医药上的应用 |
| WO2020011245A1 (zh) * | 2018-07-13 | 2020-01-16 | 江苏恒瑞医药股份有限公司 | 一种1,2,4-三嗪-3-胺类衍生物的晶型及制备方法 |
| BE1026612B1 (fr) | 2018-09-27 | 2020-07-02 | Iteos Therapeutics S A | Utilisation d’un inhibiteur d’un transporteur de la famille ent dans le traitement du cancer et combinaison de celui-ci avec un antagoniste de recepteur de l’adenosine |
| CN112955441B (zh) * | 2018-10-24 | 2024-06-18 | 里德埃克斯普洛股份公司 | 官能化氨基三嗪 |
| WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| CN111377873B (zh) * | 2018-12-28 | 2023-03-28 | 四川科伦博泰生物医药股份有限公司 | 氨基嘧啶化合物及其制备方法和用途 |
| CN113166119B (zh) | 2018-12-28 | 2024-01-05 | 四川科伦博泰生物医药股份有限公司 | 取代芳基化合物及其制备方法和用途 |
| WO2020135195A1 (zh) | 2018-12-28 | 2020-07-02 | 四川科伦博泰生物医药股份有限公司 | 氨基吡啶类化合物及其制备方法和用途 |
| BR112021013936A2 (pt) | 2019-01-18 | 2021-09-21 | Nuvation Bio Inc. | Compostos heterocíclicos como antagonistas de adenosina |
| CN113939291A (zh) | 2019-01-18 | 2022-01-14 | 诺维逊生物股份有限公司 | 1,8-萘啶酮化合物及其用途 |
| WO2020163382A1 (en) * | 2019-02-04 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| CN119320388A (zh) | 2019-02-04 | 2025-01-17 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| KR102913697B1 (ko) * | 2019-02-05 | 2026-01-15 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| JP7551629B2 (ja) | 2019-02-05 | 2024-09-17 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| EP3920918A4 (en) * | 2019-02-05 | 2022-11-16 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING |
| EP3920919A4 (en) * | 2019-02-05 | 2023-03-29 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATING SPLICE |
| JP7603594B2 (ja) | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| WO2020163544A1 (en) | 2019-02-06 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| ES3032659T3 (en) | 2019-02-15 | 2025-07-23 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| BR112021015672A2 (pt) | 2019-02-15 | 2021-10-05 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos |
| CN112608330B (zh) | 2019-07-30 | 2021-09-28 | 杭州阿诺生物医药科技有限公司 | A2a和/或a2b受体抑制剂 |
| CN112479956A (zh) | 2019-07-30 | 2021-03-12 | 杭州阿诺生物医药科技有限公司 | 一种用于制备腺苷受体抑制剂中间体的方法 |
| TW202124444A (zh) | 2019-09-16 | 2021-07-01 | 美商表面腫瘤學公司 | 抗ｃｄ３９抗體組合物及方法 |
| JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
| TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與ｅｎｔｐｄ２抗體之組合療法 |
| TWI875823B (zh) | 2019-09-25 | 2025-03-11 | 美商表面腫瘤學有限責任公司 | 抗ｉｌ-２７抗體及用途 |
| WO2021071984A1 (en) * | 2019-10-08 | 2021-04-15 | Skyhawk Therapeutics, Inc. | Compounds for modulating splicing |
| WO2021110697A1 (en) * | 2019-12-02 | 2021-06-10 | Astrazeneca Ab | Solid pharmaceutical formulations of 6-(2-chloro-6-methylpyridin-4-yl)-5-(-4-fluorophenyl)-1,2,4-triazin-3-amine |
| KR20220116257A (ko) | 2019-12-20 | 2022-08-22 | 노파르티스 아게 | 골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물 |
| CN115335058B (zh) * | 2020-03-27 | 2024-12-06 | 国立大学法人京都大学 | 神经细胞变性抑制剂 |
| CN115916199A (zh) | 2020-06-23 | 2023-04-04 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案 |
| US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| EP4192454B1 (en) | 2020-08-05 | 2026-04-22 | Skyhawk Therapeutics, Inc. | Azabicyclo-amino-triazine compounds for modulating splicing for the treatment of neurological diseases |
| EP4240491A1 (en) | 2020-11-06 | 2023-09-13 | Novartis AG | Cd19 binding molecules and uses thereof |
| EP4247324A4 (en) * | 2020-11-23 | 2024-12-04 | Health Research, Inc. | COMPOUNDS AND METHODS FOR TARGETING GLUCOSE-STIMULATED PHOSPHOHISTIDINE SIGNALING AND ESOPHAGEAL CANCER GROWTH |
| EP4284510A1 (en) | 2021-01-29 | 2023-12-06 | Novartis AG | Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| CN114113628A (zh) * | 2021-11-08 | 2022-03-01 | 华东师范大学 | 多巴胺d2受体在嗅觉外周调控及制备治疗嗅觉异常药物中的应用 |
| US20250289781A1 (en) | 2022-05-02 | 2025-09-18 | Central Glass Company, Limited | Trifluoromethanesulfonylating agent composition and method for producing trifluoromethanesulfonyloxy compound or trifluoromethanesulfonyl compound |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4008232A (en) | 1975-06-23 | 1977-02-15 | Eli Lilly And Company | 3-Amino-5,6-diaryl-1,2,4-triazines |
| GB1604085A (en) | 1977-05-17 | 1981-12-02 | Diamond Shamrock Corp | Pharmaceutical preparations containing 1,2,4-triazine derivatives |
| FR2485531A1 (fr) | 1980-06-25 | 1981-12-31 | Fabre Sa Pierre | Nouveaux n-oxydes de diaryl-5,6 as triazines 1-2-4, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
| US4513135A (en) * | 1982-03-05 | 1985-04-23 | Eli Lilly And Company | Diaryl-pyrazine derivatives affecting GABA binding |
| JPH06501926A (ja) | 1990-08-06 | 1994-03-03 | 藤沢薬品工業株式会社 | 複素環式化合物 |
| CO5210943A1 (es) | 1999-05-04 | 2002-10-30 | Novartis Ag | Compuestos plaguicidas derivados de triazina, composiciones para el control de plagas que comprenden dicho compuesto y cuando menos un auxiliar y metodos para controlar plagas |
| WO2001058241A2 (en) | 2000-02-10 | 2001-08-16 | New York University | Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver |
| GB0100624D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
| TWI316055B (enExample) * | 2001-04-26 | 2009-10-21 | Nippon Shinyaku Co Ltd | |
| TWI301834B (en) * | 2001-10-22 | 2008-10-11 | Eisai R&D Man Co Ltd | Pyrimidone compound and pharmaceutical composition including the same |
| EP1485100B1 (en) | 2002-03-15 | 2010-05-05 | Vertex Pharmaceuticals Incorporated | Azinylaminoazoles as inhibitors of protein kinases |
| AU2002950853A0 (en) | 2002-08-19 | 2002-09-12 | Fujisawa Pharmaceutical Co., Ltd. | Aminopyrimidine compound and pharmaceutical use thereof |
| AU2003304527B2 (en) | 2002-12-19 | 2010-09-09 | Merck Sharp & Dohme Corp. | Uses of adenosine A2a receptor antagonists |
| GB0300783D0 (en) | 2003-01-14 | 2003-02-12 | Btg Int Ltd | Treatment of neurodegenerative conditions |
| EP1654250A1 (en) * | 2003-07-25 | 2006-05-10 | Amgen Inc. | Substituted pyridones and pyrimidinones with antiinflammatory properties |
| JP2005123160A (ja) | 2003-09-22 | 2005-05-12 | Nissan Motor Co Ltd | 燃料電池用セパレータ、燃料電池スタック及び燃料電池用セパレータの製造方法並びに燃料電池車両 |
| ES2229928B1 (es) * | 2003-10-02 | 2006-07-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirimidin-2-amina. |
| WO2005040151A1 (en) * | 2003-10-27 | 2005-05-06 | Astellas Pharma Inc. | Pyrazine derivatives and pharmaceutical use thereof |
| CN1871231A (zh) * | 2003-10-27 | 2006-11-29 | 安斯泰来制药有限公司 | 吡嗪衍生物及其医药用途 |
| FR2869906B1 (fr) | 2004-05-05 | 2006-08-11 | Fabre Pierre Dermo Cosmetique | Derives monomeriques de 5,6-diphenyl-1,2,4-triazine et leurs utilisations |
| CA2568524A1 (en) | 2004-05-28 | 2005-12-15 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| CN101060841A (zh) | 2004-06-17 | 2007-10-24 | 加利福尼亚大学董事会 | 拮抗腺苷a2a受体来改善成瘾行为的一种或多种构成 |
| CA2585490A1 (en) | 2004-11-12 | 2006-05-18 | Galapagos Nv | Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes |
| US20070135437A1 (en) | 2005-03-04 | 2007-06-14 | Alsgen, Inc. | Modulation of neurodegenerative diseases |
| AR053712A1 (es) | 2005-04-18 | 2007-05-16 | Neurogen Corp | Heteroarilos sustituidos, antagonistas de cb1 (receptor 1 canabinoide) |
| EP1902716A4 (en) | 2005-06-07 | 2009-05-13 | Kyowa Hakko Kirin Co Ltd | PROPHYLACTIC AND / OR THERAPEUTIC AGENT FOR MOTOR TROUBLESHOOTING |
| ES2270715B1 (es) * | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| EP2010514B1 (de) * | 2006-04-12 | 2010-12-29 | Basf Se | 3-(pyridin-2-yl)-[1,2,4]-triazine als fungizide |
| GB0800741D0 (en) * | 2008-01-16 | 2008-02-20 | Univ Greenwich | Cyclic triazo and diazo sodium channel blockers |
| DK2531492T3 (en) * | 2010-02-05 | 2016-07-04 | Heptares Therapeutics Ltd | 1,2,4-triazin-4-amine derivatives |
-
2011
- 2011-02-07 DK DK11704571.6T patent/DK2531492T3/en active
- 2011-02-07 HU HUE11704571A patent/HUE028640T2/en unknown
- 2011-02-07 SI SI201130846A patent/SI2531492T1/sl unknown
- 2011-02-07 WO PCT/EP2011/051755 patent/WO2011095625A1/en not_active Ceased
- 2011-02-07 PT PT117045716T patent/PT2531492T/pt unknown
- 2011-02-07 HR HRP20160636TT patent/HRP20160636T1/hr unknown
- 2011-02-07 KR KR1020187006509A patent/KR101993867B1/ko active Active
- 2011-02-07 AU AU2011212430A patent/AU2011212430B2/en active Active
- 2011-02-07 SG SG2012057436A patent/SG183146A1/en unknown
- 2011-02-07 ES ES11704571.6T patent/ES2579949T3/es active Active
- 2011-02-07 PL PL11704571.6T patent/PL2531492T3/pl unknown
- 2011-02-07 CA CA2789279A patent/CA2789279C/en active Active
- 2011-02-07 US US13/576,798 patent/US8809525B2/en active Active
- 2011-02-07 KR KR1020127023230A patent/KR101838093B1/ko active Active
- 2011-02-07 MX MX2012009073A patent/MX352415B/es active IP Right Grant
- 2011-02-07 EP EP11704571.6A patent/EP2531492B1/en active Active
- 2011-02-07 CN CN201180017840.3A patent/CN102822150B/zh active Active
- 2011-02-07 MY MYPI2012003522A patent/MY180024A/en unknown
- 2011-02-07 JP JP2012551647A patent/JP5914361B2/ja active Active
- 2011-02-07 RU RU2012137779A patent/RU2625791C2/ru active
- 2011-02-07 BR BR112012019540-9A patent/BR112012019540B1/pt active IP Right Grant
-
2012
- 2012-07-29 IL IL221160A patent/IL221160A/en active IP Right Grant
- 2012-08-01 ZA ZA2012/05788A patent/ZA201205788B/en unknown
-
2014
- 2014-07-02 US US14/322,505 patent/US9249130B2/en active Active
-
2015
- 2015-12-21 US US14/976,738 patent/US20160175314A1/en not_active Abandoned
-
2016
- 2016-06-23 SM SM201600198T patent/SMT201600198B/it unknown
- 2016-06-23 CY CY20161100573T patent/CY1117780T1/el unknown
- 2016-11-04 US US15/344,048 patent/US10112923B2/en active Active
-
2018
- 2018-10-16 US US16/161,409 patent/US10988455B2/en active Active
-
2021
- 2021-04-23 US US17/239,137 patent/US12054472B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012137779A (ru) | Производные 1,2,4-триазин-4-амина | |
| RU2500673C2 (ru) | Гетероциклические ингибиторы мек и способы их применения | |
| Bhide et al. | Discovery and preclinical studies of (R)-1-(4-(4-Fluoro-2-methyl-1 H-indol-5-yloxy)-5-methylpyrrolo [2, 1-f][1, 2, 4] triazin-6-yloxy) propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor | |
| RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
| RU2010114827A (ru) | Пиримидины, которые могут быть использованы в качестве противоинфекционных средств, и их применения | |
| JP2016522246A5 (enExample) | ||
| CN114430739A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| JP2016525078A5 (enExample) | ||
| JP2021504443A5 (enExample) | ||
| JP2017537948A5 (enExample) | ||
| RU2021129721A (ru) | Пирролопиримидины в качестве потенциаторов мвтр | |
| FI4074703T3 (fi) | Pyridinyyli-(atsa)indolsulfonamiidit | |
| HRP20161177T1 (hr) | Modulator glukagonskog receptora | |
| RU2010143455A (ru) | Имидазохинолины и производные пиримидина в качестве потенциальных модуляторов vegf-стимулируемых ангиогенных процессов | |
| JP2010510319A5 (enExample) | ||
| JP2012519693A5 (enExample) | ||
| RU2009136299A (ru) | Новые производные 3-({1,2,4}триазоло{4,3-а}пиридин-7-ил)бензамида | |
| JPWO2020017587A5 (enExample) | ||
| JP2017533968A5 (enExample) | ||
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| KR920021541A (ko) | 벤조푸란 유도체 | |
| JP2021500340A5 (enExample) | ||
| JP2021523933A5 (enExample) | ||
| RU2020106383A (ru) | 3,4-двузамещенные 3-циклобутен-1,2-дионы и их применение | |
| RU2013152961A (ru) | Изоксазолины в качестве терапевтических агентов |